Drugs such as Ozempic and Wegovy that contain the active ingredient semaglutide, currently popularized as weight loss drugs, may put users at risk of developing a rare form of blindness, four Massachusetts-based researchers warned in a study published Wednesday.
Reports from certain users of semaglutide-containing drugs prompted the researchers to pursue the question of whether the use of the drugs is associated with the development of nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) or who are overweight or obese, according to the study.
Ozempic contains lower semaglutide content and is designed specifically for patients with diabetes, while the latter has higher semaglutide content and is designed for weight loss, according to the University of California, Davis Health.
The researchers retrospectively analyzed the data of 16,827…
